Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant CAN-2409 Plus Prodrug in Combination With Chemoradiation or Stereotactic Body Radiation Therapy for Borderline Resectable Pancreatic Adenocarcinoma

NCT02446093 is registered in ClinicalTrials.gov with Candel Therapeutics, Inc. as lead sponsor.

NCT NCT02446093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02446093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant CAN-2409 Plus Prodrug in Combination With Chemoradiation or Stereotactic Body Radiation Therapy for Borderline Resectable Pancreatic Adenocarcinoma
Lead sponsor
Candel Therapeutics, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2015
Completion date
July 31, 2026
Enrollment
54 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable pancreatic adenocarcinoma